Is immunization with palivizumab really effective in high-risk children?

1Kashiwagi T, Okada Y, Nomoto K. Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan. Paediatr Drugs. 2018;20(1):97-104. doi: 10.1007/s40272-017-0264-y. Erratum in: Kashiwagi T, Okada Y, Nomoto K. Correction to: Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan. Paediatr Drugs. 2018;20(3):291. doi: 10.1007/s40272-018-0291-3 Kashiwagi T Okada Y Nomoto K Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan Paediatr Drugs 201820197 104 doi 10.1007/s40272-017-0264-y. Erratum in: Kashiwagi T, Okada Y, Nomoto K. Correction to: Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan. Paediatr Drugs. 2018;20(3):291. doi: 10.1007/s40272-018-0291-3Open DOISearch in Google Scholar

2Roglić S. Infekcije djece respiratornim sincicijskim virusom. Respiratory syncytial virus infection in children. Paediatr Croat. 2018; 62 (Supl 1): 236-41. (XXXV. Seminar Hrvatske proljetne pedijatrijske škole u Splitu od 16. do 20. 04. 2018) Roglić S Infekcije djece respiratornim sincicijskim virusom. Respiratory syncytial virus infection in children Paediatr Croat 2018 62 Supl 1 236 41 XXXV. Seminar Hrvatske proljetne pedijatrijske škole u Splitu od 16. do 20. 04. 2018Search in Google Scholar

3Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, et al.; Surveillance Committee for Severe RSV Infection. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother. 2011;17(2):254-63. doi: 10.1007/s10156-010-0121-1 Mori M Kawashima H Nakamura H Nakagawa M Kusuda S Saji T et al Surveillance Committee for Severe RSV Infection. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan J Infect Chemother 2011172254 63 doi 10.1007/s10156-010-0121-1Open DOISearch in Google Scholar

4Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, et al.; Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70(2):186-91. doi: 10.1203/PDR.0b013e318220a553 Feltes TF Sondheimer HM Tulloh RM Harris BS Jensen KM Losonsky GA et al Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease Pediatr Res 2011702186 91 doi 10.1203/PDR.0b013e318220a553Open DOISearch in Google Scholar

5Beckhaus AA, Castro-Rodriguez JA. Down Syndrome and the Risk of Severe RSV Infection: A Meta-analysis. Pediatrics. 2018;142(3):e20180225. doi: 10.1542/peds.2018-0225 Beckhaus AA Castro-Rodriguez JA Down Syndrome and the Risk of Severe RSV Infection: A Meta-analysis Pediatrics 20181423e20180225 doi 10.1542/peds.2018-0225Open DOISearch in Google Scholar

6Mori M, Onodera M, Morimoto A, Kosaka Y, Morio T, Notario GF, et al. Palivizumab use in Japanese infants and children with immunocompromised conditions. Pediatr Infect Dis J. 2014;33(11):1183-5. doi: 10.1097/INF.0000000000000392 Mori M Onodera M Morimoto A Kosaka Y Morio T Notario GF et al Palivizumab use in Japanese infants and children with immunocompromised conditions Pediatr Infect Dis J 201433111183 5 doi 10.1097/INF.0000000000000392Open DOISearch in Google Scholar

7Committee on Infectious Diseases: collaborators: Bocchini Jr JA, Bernstein HH, Bradley JS, Brady MT, Byington CL, Fisher MC, et al. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-701. doi: 10.1542/peds.2009-2345 Committee on Infectious Diseases: collaborators Bocchini Jr JA Bernstein HH Bradley JS Brady MT Byington CL Fisher MC et al From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections Pediatrics 200912461694 701 doi 10.1542/peds.2009-2345Open DOISearch in Google Scholar

8Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr. 2015;169(4):341-8. doi: 10.1001/jama-pediatrics.2014.3804 Gutfraind A Galvani AP Meyers LA Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection JAMA Pediatr 20151694341 8 doi 10.1001/jama-pediatrics.2014.3804Open DOISearch in Google Scholar

9Sánchez Luna M, Pérez Muñuzuri A, Leante Castellanos JL, Ruiz Campillo CW, Sanz López E, Benavente Fernández I, et al.; en representación de la Comisión de Estándares de la Sociedad Española de Neonatología. Recomendaciones de la Sociedad Española de Neonatología para la utilización de palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial en lactantes de alto riesgo, actualización. [An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants]. An Pediatr (Engl Ed). 2019;91(5):348-50. Spanish. doi: 10.1016/j.anpedi.2019.08.003 Sánchez Luna M Pérez Muñuzuri A Leante Castellanos JL Ruiz Campillo CW Sanz López E Benavente Fernández I et al en representación de la Comisión de Estándares de la Sociedad Española de Neonatología. Recomendaciones de la Sociedad Española de Neonatología para la utilización de palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial en lactantes de alto riesgo, actualización. [An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants] An Pediatr (Engl Ed) 2019915348 50 Spanish doi 10.1016/j.anpedi.2019.08.003Open DOISearch in Google Scholar

10American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415-20. doi: 10.1542/peds.2014-1665. Erratum in: Pediatrics. 2014;134(6):1221 American Academy of Pediatrics Committee on Infectious Diseases American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection Pediatrics 20141342415 20 doi 10.1542/peds.2014-1665. Erratum in: Pediatrics. 2014;134(6):1221Open DOISearch in Google Scholar

11Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1 Nair H Nokes DJ Gessner BD Dherani M Madhi SA Singleton RJ et al Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 201037597251545 55 doi 10.1016/S0140-6736(10)60206-1Open DOISearch in Google Scholar

12Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012;130(1):91-100.e3. doi: 10.1016/j.jaci.2012.02.010 Bacharier LB Cohen R Schweiger T Yin-Declue H Christie C Zheng J et al Determinants of asthma after severe respiratory syncytial virus bronchiolitis J Allergy Clin Immunol 2012130191 100e3 doi 10.1016/j.jaci.2012.02.010Open DOISearch in Google Scholar

13Gupta P, Beam BW, Rettiganti M. Temporal Trends of Respiratory Syncytial Virus-Associated Hospital and ICU Admissions Across the United States. Pediatr Crit Care Med. 2016;17(8):e343-51. doi: 10.1097/PCC.0000000000000850 Gupta P Beam BW Rettiganti M Temporal Trends of Respiratory Syncytial Virus-Associated Hospital and ICU Admissions Across the United States Pediatr Crit Care Med 2016178e343 51 doi 10.1097/PCC.0000000000000850Open DOISearch in Google Scholar

14Mori M, Watabe S, Taguchi T, Hasegawa H, Ishige M, Tanuma N, et al. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection. BMC Pediatr. 2021;21(1):106. doi: 10.1186/s12887-021-02567-6 Mori M Watabe S Taguchi T Hasegawa H Ishige M Tanuma N et al Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection BMC Pediatr 2021211106 doi 10.1186/s12887-021-02567-6Open DOISearch in Google Scholar

15Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Med Econ. 2012;15(5):987-96. doi: 10.3111/13696998.2012.690013 Mahadevia PJ Masaquel AS Polak MJ Weiner LB Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective J Med Econ 2012155987 96 doi 10.3111/13696998.2012.690013Open DOISearch in Google Scholar

16Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28(7):511-7. doi: 10.1038/jp.2008.28 Frogel M Nerwen C Cohen A VanVeldhuisen P Harrington M Boron M Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry J Perinatol 2008287511 7 doi 10.1038/jp.2008.28Open DOISearch in Google Scholar

17Kamori A, Morooka Y, Yamamura K, Chong PF, Kuga N, Takahata Y, et al. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study. Medicine (Baltimore). 2021;100(47):e27952. doi: 10.1097/MD.0000000000027952 Kamori A Morooka Y Yamamura K Chong PF Kuga N Takahata Y et al Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study Medicine (Baltimore) 202110047e27952 doi 10.1097/MD.0000000000027952Open DOISearch in Google Scholar

18Yamagami H, Kimura H, Hashimoto T, Kusakawa I, Kusuda S. Detection of the Onset of the Epidemic Period of Respiratory Syncytial Virus Infection in Japan. Front Public Health. 2019;7:39. doi: 10.3389/fpubh.2019.00039 Yamagami H Kimura H Hashimoto T Kusakawa I Kusuda S Detection of the Onset of the Epidemic Period of Respiratory Syncytial Virus Infection in Japan Front Public Health 2019739 doi 10.3389/fpubh.2019.00039Open DOISearch in Google Scholar

19Oliveira DB, Iwane MK, Prill MM, Weinberg GA, Williams JV, Griffin MR, et al. Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis. J Clin Virol. 2015;65:26-31. doi: 10.1016/j.jcv.2015.01.016 Oliveira DB Iwane MK Prill MM Weinberg GA Williams JV Griffin MR et al Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis J Clin Virol 20156526 31 doi 10.1016/j.jcv.2015.01.016Open DOISearch in Google Scholar

20Viguria N, Navascués A, Juanbeltz R, Echeverría A, Ezpeleta C, Castilla J. Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. Hum Vaccin Immunother. 2021;17(6):1867-72. doi: 10.1080/21645515.2020.1843336 Viguria N Navascués A Juanbeltz R Echeverría A Ezpeleta C Castilla J Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children Hum Vaccin Immunother 20211761867 72 doi 10.1080/21645515.2020.1843336Open DOISearch in Google Scholar